key: cord-0770075-5btdtz4x authors: Hassan, Ahmed O.; Feldmann, Friederike; Zhao, Haiyan; Curiel, David T.; Okumura, Atsushi; Tang-Huau, Tsing-Lee; Case, James Brett; Meade-White, Kimberly; Callison, Julie; Chen, Rita E.; Lovaglio, Jamie; Hanley, Patrick W.; Scott, Dana P.; Fremont, Daved H.; Feldmann, Heinz; Diamond, Michael S. title: A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques date: 2021-03-18 journal: Cell Rep Med DOI: 10.1016/j.xcrm.2021.100230 sha: ca31bd6cb0fd5dd6902b5d40ddb4380c2e56b61e doc_id: 770075 cord_uid: 5btdtz4x The deployment of a vaccine that limits transmission and disease likely will be required to end the Coronavirus Disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally-administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S) in the upper and lower respiratory tract of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged one month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tract after SARS-CoV-2 challenge. As this single intranasal dose vaccine confers protection against SARS-CoV-2 in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first isolated in as to the ability of these vaccines to curtail both transmission and severe disease, especially if 74 upper airway infection is not prevented or reduced. Indeed, while many of the intramuscular 75 vaccines prevent SARS-CoV-2-induced pneumonia in non-human primates, they variably lung tissues after SARS-CoV-2 challenge. Thus, administration of a single dose of the ChAd-Immunogenicity analysis. We immunized 12 adult rhesus macaques (RM, Indian 97 origin), aged 3 to 11 years old, with ChAd-Control or ChAd-SARS-CoV-2-S (n = 6 each; 3 98 females, 3 males). RM received a single immunization of 10 11 viral particles of the ChAd vectors 99 by the intranasal route without adjuvant at day -28 (Fig 1A) . All animals were pre-screened for 100 the absence of neutralizing antibody responses against the simian AdV vector (Fig S1) as well 101 as against SARS-CoV-2. Three weeks after vaccination (day -7), we detected IgG antibodies against the S and RBD proteins by ELISA in all RM immunized with ChAd-SARS-CoV-2-S but not ChAd-Control vaccines (Fig 1B-C) . We also detected low levels of SARS-CoV-2-specifc IgA 104 in serum at this time point (Fig 1D) . Neutralizing antibody responses were assessed using an 105 infectious SARS-CoV-2 focus-reduction neutralization test 27 and were detected in all RMs 106 immunized with ChAd-SARS-CoV-2-S (Fig 1E) . T cell responses specific to SARS-CoV-2 S 107 were assessed by an IFN-γ ELISPOT assay on PBMCs isolated two weeks after vaccination 108 (day -14). All RMs immunized with ChAd-SARS-CoV-2-S but not ChAd-Control developed T cell (gemomic RNA). Whereas most of the RMs immunized with ChAd-Control vaccine showed high 123 levels of viral RNA through day+5 with some animals persisting through day +7, lower levels 124 were observed in RMs immunized with ChAd-SARS-CoV-2-S (Fig 2B-E) . At day +1, only one 125 RM vaccinated with ChAd-SARS-CoV-2-S showed detectable infectious virus in nasal swabs by 126 a tissue culture infectious dose (TCID 50 ) assay, whereas 4 of 6 RM immunized with ChAd- Control were positive (Fig 2F) . At later time points, infectious virus was not recovered from the Table 1) . At day +3, 137 only one (from ChAd-control immunized RM) of the 12 BAL fluid samples collected was positive 138 for infectious virus. Consistent with these results, at days +1 and +3, substantially higher levels 139 (100 and 50-fold, respectively) of viral RNA were detected in the BAL fluid of RM immunized 140 with ChAd-control compared to ChAd-SARS-CoV-2-S (Fig 3A-B) . protection, the viral RNA levels in BAL fluid at day +3 were compared to the serum neutralizing 148 or anti-S IgG titers obtained three weeks after immunization. We observed an inverse better than anti-S IgG levels (P = 0.029, R 2 = 0.74 versus P = 0.21, R 2 = 0.36, respectively) ( Fig 3E-F) . Thus, serum neutralizing antibody titers may serve as a correlate of protection for the 153 ChAd-SARS-CoV-2-S vaccine. To determine whether antibody activity in sera could be boosted, we collected sera from ChAd-SARS-CoV-2-S-immunized RMs at D+7 after SARS-CoV-2 155 challenge. We observed an approximately 10-fold increase in serum neutralizing titers (Fig 3G) 156 compared to those measured one week before challenge (see Fig 1E) . At this time point, we 157 also observed substantially higher levels of anti-SARS-CoV-2 IgA in RMs that had been 158 vaccinated with ChAd-SARS-CoV-2-S (Fig 3H) . These findings suggest that a booster dose of 159 ChAd-SARS-Cov-2-S might enhance the serum neutralizing antibody, mucosal immunity, and In summary, our studies establish that immunization of primates with ChAd-SARS-CoV- CoV-2 equally split between the two routes in a total volume of 5 mL (4 mL intrabronchial; 1 mL 377 intranasal). Animals were monitored at least twice daily throughout the study using an Reactions were stopped with 50 µL of 2 M sulfuric acid. Optical density (450 nm Chandrashekar A, et al. (2020) . DNA vaccine protection against SARS-CoV-2 in SARS-CoV-2 neutralizing antibody 542 structures inform therapeutic strategies Ultrapotent human antibodies protect against SARS-546 CoV-2 challenge via multiple mechanisms De novo design of picomolar SARS-CoV-2 miniprotein inhibitors Rational Vaccine Design in the Time of COVID-19 Rapid COVID-19 vaccine development Safety and Efficacy of the BNT162b2 mRNA 560 Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Interim Results of a Phase 1-2a Trial of 568 S Covid-19 Vaccine Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses Neutralizing antibody and soluble ACE2 inhibition of a replication-598 competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 SARS-CoV-2 infection protects against rechallenge 607 in rhesus macaques Respiratory disease in 611 rhesus macaques inoculated with SARS-CoV-2 A single intranasal or intramuscular immunization with 615 chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in 616 hamsters Rapid development of an inactivated vaccine candidate for SARS-CoV-2 Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in 641 nonhuman primates Immunization with modified vaccinia virus Ankara-based 645 recombinant vaccine against severe acute respiratory syndrome is associated with enhanced 646 hepatitis in ferrets A double-inactivated severe acute respiratory 650 syndrome coronavirus vaccine provides incomplete protection in mice and induces increased 651 eosinophilic proinflammatory pulmonary response upon challenge Anti-spike IgG causes severe acute lung injury by skewing macrophage responses 656 during acute SARS-CoV infection Thoracic radiography as a refinement methodology for the study of H1N1 influenza 660 in cynomologus macaques (Macaca fascicularis) Modification of a common BAL technique to enhance sample diagnostic value The polypeptides of adenovirus. I Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12